Citations

Clear

1792 citation(s) found for "Stephanie".

Clinical Disease Progression and Biomarkers in Niemann–Pick Disease Type C: A Prospective Cohort Study
Mengel, Eugen , Bembi, Bruno , Grünewald, Stephanie , Héron, Bénédicte , Maier, Esther M. , Roubertie, Agathe , Santra, Saikat , Day, Simon , Symonds, Tara , Hudgens, Stacie , Guldberg, Christina, Ingemann, Linda, Petersen, Nikolaj HT, Kirkegaard, Thomas , Dali, Christine í, Toro, Mireia del , Deodato, Federica , Gautschi, Matthias , Grønborg, Sabine , Tylki‐Szymańska, Anna , Day, Simon, Patterson, Marc C. , Mengel, Eugen

Mayo Clinic

No container title available | June 15, 2020 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-35139/v1 Get It

Abstract BackgroundNiemann–Pick disease type C (NPC) is a rare, progressive, neurodegenerative disease associated with neurovisceral manifestations resulting from lysosomal dysfunction and aberrant lipid accumulation. A multicentre, prospective observational study (ClinicalTrials.gov ID:NCT02435030) of individuals with genetically confirmed NPC1 or NPC2 receiving routine clinical care was conducted, to prospectively characterize and measure NPC disease progression and to investigate potential NPC-related biomarkers versus healthy individuals. Progression was measured using the abbreviated 5-domain NPC Clinical Severity Scale (NPCCSS), 17-domain NPCCSS and NPC clinical database (NPC-cdb) score. Cholesterol esterification and heat shock protein 70 (HSP70) levels were assessed from peripheral blood mononuclear cells (PBMCs), cholestane-3β,5α-,6β-triol (cholestane-triol) from serum, and unesterified cholesterol from both PBMCs and skin biopsy samples. The inter- and intra-rater reliability of the 5-domain NPCCSS was assessed by 13 expert clinicians’ rating of four participants via video recordings, repeated after ≥3 weeks. Intraclass correlation coefficients (ICCs) were calculated.ResultsOf the 36 individuals with NPC (2–18 years) enrolled, 31 (86.1%) completed the 6–14-month observation period; 30/36 (83.3%) were receiving miglustat as part of routine clinical care. A mean (±SD) increase in 5-domain NPCCSS scores of 1.4 (±2.9) was observed, corresponding to an annualized progression rate of 1.5. On the 17-domain NPCCSS, a mean (±SD) progression of 2.7 (±4.0) was reported. Compared with healthy individuals, the NPC population had significantly lower levels of cholesterol esterification (p<0.0001), HSP70 (p<0.0001) and skin unesterified cholesterol (p=0.0006). Cholestane-triol levels were significantly higher in individuals with NPC versus healthy individuals (p=0.008) and correlated with the 5-domain NPCCSS (Spearman’s correlation coefficient=0.265, p=0.0411). The 5-domain NPCCSS showed high ICC agreement in inter-rater reliability (ICC=0.995) and intra-rater reliability (ICC=0.937).ConclusionsProgression rates observed were consistent with other reports on disease progression in NPC. The 5-domain NPCCSS reliability study supports its use as an abbreviated alternative to the 17-domain NPCCSS that focuses on the most relevant domains of the disease. The data support the use of cholestane-triol as a disease monitoring biomarker and the novel methods of measuring unesterified cholesterol could be applicable to support NPC diagnosis. Levels of HSP70 in individuals with NPC were significantly decreased compared with healthy individuals.Trial Registration: CT-ORZY-NPC-001: ClincalTrials.gov NCT02435030, Registered 6 May 2015, https://clinicaltrials.gov/ct2/show/NCT02435030; EudraCT 2014-005194-37, Registered 28 April 2015, https://www.clinicaltrialsregister.eu/ctr-search/trial/2014-005194-37/DE. OR-REL-NPC-01: Unregistered.
Common Genetic Variation Indicates Separate Causes for Periventricular and Deep White Matter Hyperintensities
Armstrong, Nicola J. , Mather, Karen A. , Sargurupremraj, Muralidharan , Knol, Maria J. , Malik, Rainer, Satizábal, Claudia L. , Yanek, Lisa R., Wen, Wei , Guðnason, Vilmundur , Dueker, Nicole , Elliott, Lloyd T. , Hofer, Edith, Bis, Joshua C. , Jahanshad, Neda , Li, Shuo , Logue, Mark, Scholz, Markus , Smith, Albert V. , Trompet, Stella , Alfaro‐Almagro, Fidel , Ames, David, Amin, Najaf , Beiser, Alexa S., Brodaty, Henry , Fennema‐Notestine, Christine , Gampawar, Piyush , Gottesman, Rebecca, Griffanti, Ludovica , Kral, Brian G. , Lampe, Leonie, Liewald, David C. , Maillard, Pauline , Marchini, Jonathan, Bastin, Mark E., Pirpamer, Lukas , Roshchupkin, Gennady V. , Stott, David J., Thalamuthu, Anbupalam , Tzourio, Christophe , Grond, Jeroen van der , Vernooij, Meike W. , Witte, A. Veronica , Wright, Margaret J. , Yang, Qiong, Siggurdsson, Siggi, Psaty, Bruce M., Villringer, Arno , Schmidt, Helena, Duijn, Cornelia M. van , Jukema, J. Wouter , Dichgans, Martin , Sacco, Ralph L., Kremen, William S., Becker, Lewis C. , Thompson, Paul M., Mosley, Thomas H. , Wardlaw, Joanna M. , Ikram, M. Arfan , Adams, Hieab H.H. , Seshadri, Sudha , Sachdev, Perminder S. , Smith, Stephen M. , Launer, L. J., Longstreth, W.T. , DeCarli, Charles , Schmidt, Reinhold, Fornage, Myriam , Debette, Stéphanie , DeCarli, Charles , Dichgans, Martin , Wardlaw, Joanna Marguerite , Thalamuthu, Anbupalam , Wen, Wei , Adams, Hieab H H , Satizabal, Claudia L , Seshadri, Sudha , Brodaty, Henry , Sachdev, Perminder S , Wright, Margaret J , Tzourio, Christophe , van Duijn, Cornelia M , Debette, Stephanie , Smith, Albert V , Maillard, Pauline , Hofer, Edith , Luciano, Michelle , Vojinović, Dina , Xia, Rui , Amouyel, Philippe , Deary, Ian J. , Jack, Clifford R. , Jenkinson, Mark , Jiang, Jiyang , Kwok, John B. , Marchini, Jonathan , Mazoyer, Bernard , Romero, José R. , Schofield, Peter R. , Schroeter, Matthias L , Trollor, Julian N , Morris, Zoë , Psaty, Bruce M. , Håberg, Asta K , Wright, Clinton B. , Thompson, Paul M. , Nyquist, Paul

Mayo Clinic

Stroke | June 10, 2020 | Volume: 51 | Issue: 7 | Pages: 2111-2121

10.1161/strokeaha.119.027544 | PMID 32517579 Get It

Background and Purpose: Periventricular white matter hyperintensities (WMH; PVWMH) and deep WMH (DWMH) are regional classifications of WMH and reflect proposed differences in cause. In the first study, to date, we undertook genome-wide association analyses of DWMH and PVWMH to show that these phenotypes have different genetic underpinnings. Methods: Participants were aged 45 years and older, free of stroke and dementia. We conducted genome-wide association analyses of PVWMH and DWMH in 26,654 participants from CHARGE (Cohorts for Heart and Aging Research in Genomic Epidemiology), ENIGMA (Enhancing Neuro-Imaging Genetics Through Meta-Analysis), and the UKB (UK Biobank). Regional correlations were investigated using the genome-wide association analyses -pairwise method. Cross-trait genetic correlations between PVWMH, DWMH, stroke, and dementia were estimated using LDSC. Results: In the discovery and replication analysis, for PVWMH only, we found associations on chromosomes 2 ( NBEAL ), 10q23.1 ( TSPAN14/FAM231A ), and 10q24.33 ( SH3PXD2A). In the much larger combined meta-analysis of all cohorts, we identified ten significant regions for PVWMH: chromosomes 2 (3 regions), 6, 7, 10 (2 regions), 13, 16, and 17q23.1. New loci of interest include 7q36.1 ( NOS3 ) and 16q24.2. In both the discovery/replication and combined analysis, we found genome-wide significant associations for the 17q25.1 locus for both DWMH and PVWMH. Using gene-based association analysis, 19 genes across all regions were identified for PVWMH only, including the new genes: CALCRL (2q32.1), KLHL24 (3q27.1), VCAN (5q27.1), and POLR2F (22q13.1). Thirteen genes in the 17q25.1 locus were significant for both phenotypes. More extensive genetic correlations were observed for PVWMH with small vessel ischemic stroke. There were no associations with dementia for either phenotype. Conclusions: Our study confirms these phenotypes have distinct and also shared genetic architectures. Genetic analyses indicated PVWMH was more associated with ischemic stroke whilst DWMH loci were implicated in vascular, astrocyte, and neuronal function. Our study confirms these phenotypes are distinct neuroimaging classifications and identifies new candidate genes associated with PVWMH only.
Hypopharyngeal Squamous Cell Carcinoma in Sisters with LMNA Associated Familial Partial Lipodystrophy: A Case Report and Review of the Literature
Youssef, Stephanie J. , Macielak, Robert J. , Schimmenti, Lisa A. , Chatzopoulos, Kyriakos , Schimmenti, Lisa A , Price, Daniel L.

Mayo Clinic

Annals of Otology, Rhinology & Laryngology | June 10, 2020 | Volume: 129 | Issue: 12 | Pages: 1243-1246

10.1177/0003489420933645 | PMID 32517491 Get It

Objectives: LMNA-associated familial partial lipodystrophy (FPLD) is a rare autosomal dominant A-type laminopathy characterized by variable loss and redistribution of subcutaneous adipose tissue, dyslipidemia, and insulin resistance. Though A-type lamins play a key role in nuclear membrane structure and regulation of cell proliferation, an association between cancer and LMNA-associated FPLD has not been reported. Methods and Results: This report outlines the case of two biological sisters with LMNA-associated FPLD who developed hypopharyngeal squamous cell carcinoma in the absence of any other risk factors for head and neck cancer. Conclusion: These observations prompt further investigation into the potential role of A-type lamins in the development and progression of head and neck cancers.
P1799GENOTYPE-PHENOTYPE CORRELATION IN A PEDIATRIC ADPKD COHORT
Giel, Dorien Van , Breysem, Luc , Hindryckx, An , Decuypere, Jean-Paul , Corveleyn, Anniek , Audrézet, Marie‐Pierre , Rechter, Stéphanie De , Janssens, Peter , Bammens, Bert , Férec, Claude , Vennekens, Rudi , Harris, Peter C. , Mekahli, Djalila

Mayo Clinic

Nephrology Dialysis Transplantation | June 6, 2020 | Volume: 35 | Issue: Supplement_3 | Pages: No page available

10.1093/ndt/gfaa144.p1799 Get It

Abstract Background and Aims The correlation between genotype and phenotype is well described in ADPKD adults. PKD2 is milder than PKD1 disease, with end stage kidney disease (ESKD) occurring on average 20 years later, and patients with PKD1 truncating mutations having a more severe outcome than PKD1 non-truncating mutations. Still, large differences in outcome occur even within families carrying the same gene variation. Only a few cases series reported the genetic profile of severely affected ADPKD children and suggest an additional effect of hypomorphic genes. We therefore aim to analyse the geno-phenotype profile in a well characterized pediatric ADPKD cohort. Method Clinical, familial, biological and imaging data were collected longitudinally in children diagnosed with ADPKD. Genotypic analysis was done using a custom Agilent SureSelect gene panel containing 136 ciliopathy-associated genes, including PKD1 and PKD2. Mutations and/or variants identified were individually evaluated for pathogenicity. Results 57 ADPKD children from 44 families were diagnosed at a mean (± SD) age of 4.1 (±4.8) years. ADPKD diagnosis was made in 32 children (56%) because of asymptomatic screening as requested by the family; 7 (12%) due to presenting symptoms (6 due to urinary tract infection and 1 due to post-traumatic macroscopic hematuria); 9 (16%) due to a coincidental finding of renal cysts on US performed for another reason and in 9 cases (16%) a prenatal diagnosis was performed. Twenty-nine children (51%) met the definition of very-early onset (VEO) disease. We identified pathogenic mutations in 100% of our patients, in which the prevalence of PKD1 truncating, PKD1 non-truncating, PKD2 and GANAB mutations was 75%, 19%, 4%, and 2%, respectively. Four cases (7%) were due to a de novo mutation. Interestingly, in 29 patients (51%) the germline mutation was the only identified mutation. However, in the rest of the subjects additional variants were identified in other ciliopathy-associated genes. In 12 cases (21%) the additional identified variants found in either the PKD, PMM2, HNF1B, DNAJC1, CEP290, NEK1, MKKS, NPHP4 or PKHD1 genes were scored to have a potential phenotypic effect, which will be evaluated by continued follow-up of this cohort. Conclusion We report the first large cohort of genotyped ADPKD children, including an extensive panel of ciliopathy genes next to the PKD genes. Interestingly, we found a high prevalence of additional and potentially modifying variants in this young population.
Ten (No, Make that 11) Ways the Migraine Mavens Have Changed the Conversation About Sexism in Medicine
Loder, Elizabeth , Starling, Amaal J. , Borrero‐Mejias, Clarimar, Burch, Rebecca , Rastogi, Reena Gogia , Gautreaux, Jessica , Nahas, Stephanie J. , Monteith, Teshamae , Monteith, Teshamae S , Metzler, Abby

Mayo Clinic

Headache: The Journal of Head and Face Pain | May 31, 2020 | Volume: 60 | Issue: 6 | Pages: 1042-1046

10.1111/head.13840 Get It

Workshop on normal reference ranges for estradiol in postmenopausal women: commentary from The North American Menopause Society on low-dose vaginal estrogen therapy labeling
Pinkerton, JoAnn V. , Liu, James , Thurston, Rebecca C. , Joffe, Hadine , Santoro, Nanette F. , Faubion, Stephanie S. , Manson, JoAnn E.

Mayo Clinic

Menopause | May 27, 2020 | Volume: 27 | Issue: 6 | Pages: 611-613

10.1097/gme.0000000000001576 | PMID 32459749 Get It

Scientific Societies Fostering Inclusive Scientific Environments through Travel Awards: Current Practices and Recommendations
Vega, Leticia R. , Primus, Clara, Etson, Candice M. , Guillory, Ashley N. , Edwards, Ashanti, Flores, Sonia C., Fry, Catherine, Ingram, Susan , Lawson, Mark A. , McGee, Richard , Paxson, Stephanie, Phelan, Laura, Suggs, Kirsta, Vuong, Elizabeth, Hammonds-Odie, Latanya , Leibowitz, Michael J. , Zavala, MariaElena, Luján, J. Luis , Ramirez-Alvarado, Marina, Segarra, Verónica A. , Ramı́rez-Alvarado, Marina

Mayo Clinic

CBE—Life Sciences Education | May 26, 2020 | Volume: 19 | Issue: 2 | Pages: es3

10.1187/cbe.19-11-0262 | PMID 32453676 Get It

This essay compares the approaches that scientific societies in the ACCESS meta-organization use to implement and assess travel award programs for URM trainees and presents a set of recommendations, including both short- and long-term outcomes assessment in populations of interest and specialized programmatic activities coupled to travel award programs.
The role of long non-coding RNA ANRIL in chemosensitivity in osteosarcoma and clinical outcomes.
Lee, Adam M , Moore, Elise , Ferdjallah, Asmaa , Lee, Adam M. , Nath, Aritro , Huang, R. Stephanie

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: e22515-e22515

10.1200/jco.2020.38.15_suppl.e22515 Get It

e22515 Background: Osteosarcoma is a skeletal malignancy affecting children, adolescents, and young adults. Surgical resection and chemotherapy are the mainstay of therapy with a three-drug regimen - cisplatin, doxorubicin, and methotrexate. However, prognosis remains poor mainly due to chemo-resistance and/or metastases. Emerging evidence has shown that long non-coding RNAs (lncRNAs) are implicated in drug sensitivity and cancer metastasis. Our lab has recently identified strong significant association between cellular sensitivity to cisplatin and doxorubicin and expression of a lncRNA ANRIL in a collection of osteosarcoma cell lines. Methods: SiRNA knockdown experiments were carried out in an osteosarcoma cell line, SAOS2. Cells were exposed to multiple concentrations of cisplatin or doxorubicin. Cellular sensitivity to these two drugs was quantified after siRNA experiment with siRNA targeting ANRIL and scramble control at 24, 48 and 72h. Clinical outcome analysis was performed using data from the Therapeutically Applicable Research to Generate Effective Treatments (TARGET) initiative. Results: We successfully knocked down ANRIL expression in SAOS2 cells with 88.5% efficiency. A significant decreased rate of proliferation was detected for cisplatin (7 uM, 72h) in knockdown cells (16.5% +/- 4.1) compared to scramble control (26.4% +/- 0.8). The cisplatin IC50 was decreased in the siRNA knockdown condition as compared to scramble control at 72h (p = 0.02). For doxorubicin, the IC50 was also significantly decreased in the siRNA knockdown condition as compared to scramble control (p = 0.002 and 0.007 at 24h and 72h, respectively). Survival outcomes, metastases at diagnosis, and percent necrosis (an indicator of treatment response) were evaluated in TARGET osteosarcoma patients (n = 121 and n = 43 for OS, percent necrosis, respectively) with varying degrees of ANRIL expression. Above the median ANRIL expression was associated with a greater number of death (p = 0.004) and higher chances of metastases at diagnosis (p = 0.013). Conclusions: Reducing ANRIL expression led to increased cellular sensitivity to cisplatin and doxorubicin, two key treatment agents for osteosarcoma. Higher ANRIL expression was significantly associated with higher rates of osteosarcoma death and metastases at diagnosis in a clinical cohort of patients. These findings may suggest ANRIL serves as a novel biomarker of cisplatin and doxorubicin sensitivity in osteosarcoma.
A randomized phase II study of cabozantinib and nivolumab versus nivolumab in recurrent endometrial cancer.
Lheureux, Stéphanie , Block, Matthew S. , McHale, Michael S., Werner, Theresa L. , Duska, Linda , Kehoe, Siobhan M., Wang, Lisa , Wildman, Rachel P., Wang, Ben X. , Matei, Daniela , Konstantinopoulos, Panagiotis A. , Jewell, Andrea , Gaillard, Stéphanie , McCourt, Carolyn Kay , Temkin, Sarah M. , Girda, Eugenia , Backes, Floor , Wildman, Rachel, Ohashi, Pamela S. , Wright, John Joseph, Fleming, Gini F.

Mayo Clinic

Journal of Clinical Oncology | May 25, 2020 | Volume: 38 | Issue: 15_suppl | Pages: 6010-6010

10.1200/jco.2020.38.15_suppl.6010 Get It

6010 Background: The efficacy of treatment for recurrent endometrial cancer (EC) remains limited. Vascular endothelial growth factor and inflammatory chemokines are proangiogenic factors and immune modulators involved in immune suppression. Reprogramming the tumor microenvironment by combining antiangiogenic and immunotherapy (IO) could enhance antitumor responses. Methods: A 2:1 randomized phase 2 trial compared the combination of cabozantinib and nivolumab (Arm A) versus nivolumab (Arm B) in recurrent EC. Primary endpoint was progression free survival (PFS) assessed by RECIST 1.1 (NCT03367741). Women with recurrent measurable EC were eligible. There were no limits on prior therapy, but at least one prior platinum-based chemotherapy was required. Patients (pts) were stratified according to MSI status and assessed by CT every 8 weeks. Cabozantinib was given at 40 mg daily (Arm A) and nivolumab at 240 mg, on D1 and D15 of a 28-day cycle for 4 cycles, followed by 480 mg every 4 weeks (Arms A & B). Pts with carcinosarcoma or prior IO were enrolled in an exploratory cohort and received combination treatment (Arm C). A baseline biopsy was required for all pts. CyTOF analysis was performed on fresh biopsies. Results: 76 evaluable pts were enrolled (Arm A: 36, Arm B: 18, Arm C: 9 carcinosarcoma, and 20 post IO including 7 pts crossed over from Arm B). 55% of pts had received ≥3 prior lines of therapy. Two pts were MSI high in Arm A and none in Arm B. The Kaplan-Meier estimated median PFS was 5.3 (95% CI: 3.5-9.5) months in Arm A and 1.9 (95% CI: 1.6-3.8) months in Arm B, with a log-rank p = 0.07, which met the significance level of 0.1 used for sample size calculation. Objective response rate (ORR) was 25% for Arm A and 16.7% for Arm B; stable disease (SD) was seen in 44.4% vs 11.1%, respectively. Clinical benefit (ORR+SD) was significantly higher in arm A vs B (p < 0.001). In Arm C-carcinosarcoma, one patient had a partial response (11.9 months duration) and four SD. In Arm C-prior IO, six pts responded and eight had SD. The most common related AEs in Arm A were diarrhea (47.2%), elevated liver enzymes (44.4%), fatigue (38.9%), anorexia, hypertension, and nausea (30.6%), mainly grade 1/2. Preliminary CyTOF analysis across treatment arms identified multiple immune subsets for further interrogation including activated CD8+ and CD4+ T cells. Conclusions: Cabozantinib plus nivolumab demonstrates improved PFS compared to nivolumab in heavily pre-treated women with recurrent EC. In-depth CyTOF analysis of the tumor microenvironment to identify predictive immune biomarkers of response is ongoing. Clinical trial information: NCT03367741.